Fennec Pharmaceuticals to Participate in Upcoming Investor Conference
Rhea-AI Summary
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) has announced its participation in the upcoming virtual H.C. Wainwright @ Home Fireside Chat Series. The event is scheduled for Monday, December 16, 2024, at 11:00 a.m. ET. The commercial stage specialty pharmaceutical company will provide a live webcast of the presentation, which will be accessible through their investor relations website. An archived version of the webcast will be made available on the company's website following the event for those unable to attend the live presentation.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, FENC declined 0.49%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the virtual H.C. Wainwright @ Home Fireside Chat Series taking place on Monday, December 16, 2024 at 11:00 a.m. ET.
To access the live webcast, please visit: https://investors.fennecpharma.com/events-and-presentations/events. An archived replay of the webcast will be available on the Fennec website following the event.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI®. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com.
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate & Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
FAQ
When is Fennec Pharmaceuticals (FENC) presenting at the H.C. Wainwright Fireside Chat Series?
How can investors access Fennec Pharmaceuticals' (FENC) H.C. Wainwright presentation?
Will there be a replay available of Fennec Pharmaceuticals' (FENC) H.C. Wainwright presentation?
What stock exchanges is Fennec Pharmaceuticals listed on?
